Comparison between &lt;i&gt;NOD2 &lt;/i&gt;gene mutation carriers (3020insC) and non-carriers in breast cancer patients: a clinicopathological and survival analysis

Huszno, Joanna; Kołosza, Zofia; Tęcza, Karolina; Pamuła‐Piłat, Jolanta; Mazur, Magdalena; Grzybowska, Ewa

doi:10.5114/amscd.2018.73276

Cited by 6 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The available published data indicate that the risk of regional lymph node metastasis in triple negative breast cancer patients is low and an SLNB procedure may be not necessary [17][18][19]. However, still, for the aforementioned patients, even after a neoadjuvant systemic therapy, an SLNB procedure should be performed.…”

Section: Resultsmentioning

confidence: 99%

Subtype of breast cancer influences sentinel lymph node positivity

et al. 2020

View full text Add to dashboard Cite

Introduction: The purpose of the study was to determine the correlation between biological subtype of breast cancer and the risk of its metastasis to a sentinel lymph node. Material and methods: In the analysed group there were 1018 women with breast cancer, clinically node negative, untreated previously. Luminal A subtype was recognised in 57% of patients. A positive sentinel lymph node was detected in 26.5% of women. Results: In the multivariate analysis only age and tumour size proved to be significant for the entire group, respectively: OR = 0.59, p = 0.0004; OR = 1.96; p < 0.0001. For Luminal A subtype values were OR = 0.51, p = 0.0007; OR = 1.78, p = 0.0045, respectively. For Luminal B patients, in women over 61 years, the risk of sentinel node metastasis probability decreases by 67% and for tumours over 21 mm the probability of positive sentinel node metastasis increases by 117%. Conclusions: According to our analysis luminal breast cancers are most numerous subtypes, and in these cases we expect more frequent instances of metastasis to a sentinel node. Following the most updated and modern procedures of breast cancer patients' treatment a procedure of sentinel lymph node biopsy is used, replacing an aggressive treatment in the axilla region. In regards to our analysis we should be more vigilant in estimation of regional lymph nodes in luminal patients under sixty with high grade tumours and the tumour diameter more than 20 mm.

show abstract

Section: Resultsmentioning

confidence: 99%

Subtype of breast cancer influences sentinel lymph node positivity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Treatment strategies are illustrated in Table III. Preliminary results of this study for BRCA, CHEK2 and NOD2 mutations have been presented in our previous publications (16)(17)(18).…”

Section: Methodsmentioning

confidence: 93%

Molecular characteristics of breast cancer according to clinicopathological factors

Huszno

Kołosza

2019

mol clin onc

Self Cite

View full text Add to dashboard Cite

The purpose of the present study was to evaluate the correlation between molecular factors such as BRCA1 DNA repair associated (BRCA1), checkpoint kinase 2 (CHEK2) and nucleotide binding oligomerization domain containing 2 (NOD2) gene mutations and clinicopathological factors in patients with breast cancer (BC). Prognostic factors were analyzed in BC patients with confirmed BRCA1 (n=73), CHEK2 (n=51) and NOD2 (n=31) mutations. The control group was selected from BC patients without mutations (n=392). The BRCA-associated cancer cases were significantly more often triple negative compared with sporadic cancer (62% vs. 14%; P=0.0001). Luminal B HER2-positive and HER2-positive non-luminal subtypes were observed more often in the control group (33 and 17%). The luminal A subtype was detected in 53% of CHEK2 mutation carriers and 45% of NOD2 mutation carriers. A lower histological grade was observed significantly more often in patients with CHEK2 mutations in comparison with the control group (88 vs. 69%; P=0.003). Lymph nodes without metastases were reported more frequently in NOD2 mutation carriers (74 vs. 54%; P=0.038), in BRCA1 mutations (73 vs. 54%; P= 0.004) and, although not significantly, in CHEK2 mutation carriers (69 vs. 54%; P=0.071) compared with the control group. In conclusion, BRCA1 mutation was associated with TNBC and the luminal B HER2 (-) subtype. HER2-positive subtypes were characteristic of the control group. CHEK2 and NOD2 mutation carriers had a more favorable profile of prognostic factors.

show abstract

“…In another study, the risk of gastric cancer in NOD2 3020insC-mutation carriers at age >50 years was more than doubled (OR = 2.479; p = 0.022) and was almost even three-fold greater among women [ 10 ]. In a previous analysis, the presence of NOD2 mutation was associated with an increased risk of a family history of breast, renal, and colorectal cancer [ 7 ]. In the present analysis, a family history of cancer, including BC, was observed more often in NOD2 -mutation compared with the control group; in patients at age ≥ 50 years.…”

Section: Discussionmentioning

confidence: 99%

“…The associated factors confirmed in the aforementioned studies were younger age at diagnosis, family history of cancer (especially breast and gastrointestinal cancer) [ 8 ], and early-stage disease [ 6 ]. In our previous study, the presence of NOD2 (3020insC) in women with BC was characterised by positive predictive factors such as: lymph nodes without metastasis (N0), lower histological grade (G<3), and negative HER2 receptor status (HER2–) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age

Huszno

Kołosza

Nycz-Bochenek

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction The purpose of the present study was to characterise patients with breast cancer (BC) and NOD2- mutation (age ≥ 50 years) according to their clinicopathological factors or family history. Patients aged ≥ 50 years were compared with the control group and with NOD2- mutation carriers aged < 50 years. Material and methods Prognostic factors were analysed in patients with BC with confirmed NOD2 c.3016_3017insC ( n = 150) mutations. The control group was selected from patients with BC without mutations ( n = 376). Results There were significant differences between NOD2 -mutation carriers and the control group aged ≥ 50 years, according to HER2 overexpression ( p = 0.0001), ER (–) ( p = 0.007), PR (–) ( p = 0.003), T1–T2 ( p = 0.011), and G3 (p = 0.036). Similarly, significant differences were observed between NOD2 -mutation carriers and the control group aged < 50 years, according to HER2 overexpression ( p = 0.0001), ER (–) ( p = 0.049), and N (+) ( p = 0.038). In patients aged ≥ 50 years, family history of cancer, including BC, was observed more often in NOD2 -mutation carriers compared with the control group of patients (OR = 1.66; p = 0.072, for BC in family history: OR = 2.65; p = 0.002). NOD2 -mutation carriers aged ≥ 50 years had significantly less frequent G3 ( p = 0.004) and HER2 overexpression ( p = 0.043) compared with patients with NOD2 mutation aged < 50 years. Conclusions The presence of the NOD2 mutation is not only characteristic of younger patients but also in patients > 50 years of age. In NOD2 -mutation carriers aged ≥ 50 years, the presence of larger tumour size, G3, or HER2 overexpression were lower compared with younger patients with NOD2 mutation.

show abstract

Comparison between <i>NOD2 </i>gene mutation carriers (3020insC) and non-carriers in breast cancer patients: a clinicopathological and survival analysis

Cited by 6 publications

References 12 publications

Subtype of breast cancer influences sentinel lymph node positivity

Subtype of breast cancer influences sentinel lymph node positivity

Molecular characteristics of breast cancer according to clinicopathological factors

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age

Contact Info

Product

Resources

About